Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient
Introduction: Over the past year, 3 agents have been approved for the treatment of melanoma by the Food and Drug Administration. These include pegylated interferon α-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for unresectab...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2013-05-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/351834 |
| _version_ | 1811255152191995904 |
|---|---|
| author | Alfredo Addeo Ciro Roberto Rinaldi |
| author_facet | Alfredo Addeo Ciro Roberto Rinaldi |
| author_sort | Alfredo Addeo |
| collection | DOAJ |
| description | Introduction: Over the past year, 3 agents have been approved for the treatment of melanoma by the Food and Drug Administration. These include pegylated interferon α-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for unresectable or metastatic melanoma. Case Presentation: We present here the case of a 65-year-old Caucasian male diagnosed with advanced melanoma in April 2011 and treated with ipilimumab (Yervoy®), a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), as second-line treatment after progression with dacarbazine, for (wild-type BRAF) metastatic melanoma. The patient was referred to us for several painful lumps on his right arm. A biopsy of one of them revealed melanoma. CT and PET scans did not show any other lesions or a primary site. The patient was started on first-line chemotherapy with dacarbazine 850 mg/m2 on day 1, every 3 weeks. After 3 cycles, the patient showed disease progression with an increase in size of the skin metastasis. Second-line treatment was started with ipilimumab 3 mg/kg on day 1, every 3 weeks. At the end of the treatment, after 4 cycles, we documented a complete clinical response with total resolution of the skin metastasis. At the time of writing this paper, our patient had finished his treatment more than 9 months earlier and is still in complete remission. Conclusion: This is a paradigmatic case where, despite extensive metastatic disease, treatment with ipilimumab has confirmed its efficacy. It is still an open question why only a minority of patients have such a remarkable response, and further trials are warranted to address this important question. |
| first_indexed | 2024-04-12T17:19:28Z |
| format | Article |
| id | doaj.art-11309585d2e84233af00513cafa3768a |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-12T17:19:28Z |
| publishDate | 2013-05-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-11309585d2e84233af00513cafa3768a2022-12-22T03:23:31ZengKarger PublishersCase Reports in Oncology1662-65752013-05-016228528810.1159/000351834351834Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma PatientAlfredo AddeoCiro Roberto RinaldiIntroduction: Over the past year, 3 agents have been approved for the treatment of melanoma by the Food and Drug Administration. These include pegylated interferon α-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for unresectable or metastatic melanoma. Case Presentation: We present here the case of a 65-year-old Caucasian male diagnosed with advanced melanoma in April 2011 and treated with ipilimumab (Yervoy®), a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), as second-line treatment after progression with dacarbazine, for (wild-type BRAF) metastatic melanoma. The patient was referred to us for several painful lumps on his right arm. A biopsy of one of them revealed melanoma. CT and PET scans did not show any other lesions or a primary site. The patient was started on first-line chemotherapy with dacarbazine 850 mg/m2 on day 1, every 3 weeks. After 3 cycles, the patient showed disease progression with an increase in size of the skin metastasis. Second-line treatment was started with ipilimumab 3 mg/kg on day 1, every 3 weeks. At the end of the treatment, after 4 cycles, we documented a complete clinical response with total resolution of the skin metastasis. At the time of writing this paper, our patient had finished his treatment more than 9 months earlier and is still in complete remission. Conclusion: This is a paradigmatic case where, despite extensive metastatic disease, treatment with ipilimumab has confirmed its efficacy. It is still an open question why only a minority of patients have such a remarkable response, and further trials are warranted to address this important question.http://www.karger.com/Article/FullText/351834MelanomaIpilimumabComplete response |
| spellingShingle | Alfredo Addeo Ciro Roberto Rinaldi Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient Case Reports in Oncology Melanoma Ipilimumab Complete response |
| title | Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient |
| title_full | Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient |
| title_fullStr | Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient |
| title_full_unstemmed | Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient |
| title_short | Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient |
| title_sort | treatment with ipilimumab a case report of complete response in a metastatic malignant melanoma patient |
| topic | Melanoma Ipilimumab Complete response |
| url | http://www.karger.com/Article/FullText/351834 |
| work_keys_str_mv | AT alfredoaddeo treatmentwithipilimumabacasereportofcompleteresponseinametastaticmalignantmelanomapatient AT cirorobertorinaldi treatmentwithipilimumabacasereportofcompleteresponseinametastaticmalignantmelanomapatient |